Exploring how interferon lambda helps protect against severe Clostridioides difficile infections
Investigating the role of interferon lambda in protection against severe Clostridioides difficile infection
This study is looking at how a substance called interferon lambda might help protect people from serious infections caused by Clostridioides difficile, which often leads to gut problems in hospitals, and it hopes to find new ways to help heal the gut and improve treatment options for patients.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11060175 on NIH RePORTER |
What this research studies
This research investigates the role of interferon lambda in providing protection against severe infections caused by Clostridioides difficile, a leading cause of gastrointestinal infections in hospitals. The study focuses on understanding how interferon lambda can stimulate the repair of the intestinal barrier damaged by the bacteria's toxins. By using a specific treatment that activates the immune response, researchers aim to identify the mechanisms through which this protection occurs. Patients may benefit from insights that could lead to new treatment options beyond traditional antibiotics.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have experienced recurrent Clostridioides difficile infections or are at high risk for such infections.
Not a fit: Patients who have not been diagnosed with Clostridioides difficile infections or those with other unrelated gastrointestinal conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies that reduce the severity and recurrence of Clostridioides difficile infections.
How similar studies have performed: Previous research has shown promise in using immune modulators like interferon lambda for other conditions, suggesting potential for success in this novel application.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Mears, Kevin Stanton — University of Pennsylvania
- Study coordinator: Mears, Kevin Stanton
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.